Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
KRYSTAL BIOTECH RG (NQ: KRYS)
18.33 USD  +0.33 (+1.83%)
Official Closing Price  /  Updated: 8:00 PM EDT, Jul 20, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 41,026
Open 17.77
Bid (Size) 13.25 (900)
Ask (Size) 19.99 (1000)
Prev. Close 18.00
Today's Range 17.77 - 18.53
52wk Range 8.030 - 19.25
Shares Outstanding 10,309,615
Dividend Yield N/A
Performance
YTD
+99.67%
+99.67%
1 Month
+20.12%
+20.12%
3 Month
+81.49%
+81.49%
6 Month
+78.83%
+78.83%
1 Year
+72.27%
+72.27%
Top News
More News
Krystal Biotech to Present Update on KB103 Program for Treatment of Dystrophic Epidermolysis Bullosa at debra Care Conference 2018
Krystal Biotech Inc., (“Krystal”) (NASDAQ:KRYS), a gene therapy company developing topical and intradermal “off-the-shelf” treatments for rare dermatological diseases, today announces a presentation on... Read More
from GlobeNewswire News Releases
U.S. FDA Grants Fast Track Designation for Krystal Biotech’s KB103 for the Treatment of Dystrophic Epidermolysis Bullosa
Krystal Biotech Inc., (“Krystal”) (NASDAQ:KRYS), a gene therapy company developing topical and intradermal "off-the-shelf" treatments for rare dermatological diseases, today announces that the U.S.... Read More
from GlobeNewswire News Releases
More News
Read More
Krystal Biotech Announces Dosing of First Patient in the Phase 1/2 trial of KB103, a First-in-Class Topical Gene Therapy for the Treatment of Dystrophic Epidermolysis Bullosa
from GlobeNewswire News Releases
Krystal Biotech Presents In Vivo KB103 Data at the International Investigative Dermatology Conference that Show Human COL7 Incorporating into Anchoring Fibrils with Proper Structural Orientation
from GlobeNewswire News Releases
Krystal Biotech Reports First Quarter 2018 Financial Results and Provides Corporate Update
from GlobeNewswire News Releases
Krystal Biotech Announces FDA Clearance of IND on KB103 to Begin Enrolling Patients for the Treatment of Dystrophic Epidermolysis Bullosa
from GlobeNewswire News Releases
Krystal Biotech’s KB103 Receives Orphan Medicinal Product Designation in Europe for Dystrophic Epidermolysis Bullosa
from GlobeNewswire News Releases
Krystal Biotech Presents Their Skin TARgeted Delivery Platform at the World Orphan Drug Congress USA
from GlobeNewswire News Releases
Krystal Submits Investigational New Drug (IND) Application for KB103, Topical Gene Therapy Candidate for Dystrophic Epidermolysis Bullosa
from GlobeNewswire News Releases
BRIEF-Krystal Biotech Announces FDA Clearance Of IND On KB103 For The Treatment Of Dystrophic Epidermolysis Bullosa
category companyNews
from Reuters: Company News
BRIEF-Krystal Biotech’S Kb103 Receives Orphan Medicinal Product Designation In Europe For Dystrophic Epidermolysis Bullosa
category companyNews
from Reuters: Company News
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.